Please use this identifier to cite or link to this item: https://doi.org/10.3390/medicina54010008
DC FieldValue
dc.titleAngiogenesis: Managing the culprits behind tumorigenesis and metastasis
dc.contributor.authorYehya A.H.S.
dc.contributor.authorAsif M.
dc.contributor.authorPetersen S.H.
dc.contributor.authorSubramaniam A.V.
dc.contributor.authorKono K.
dc.contributor.authorMajid A.M.S.A.
dc.contributor.authorOon C.E.
dc.date.accessioned2019-03-12T08:10:13Z
dc.date.available2019-03-12T08:10:13Z
dc.date.issued2018
dc.identifier.citationYehya A.H.S., Asif M., Petersen S.H., Subramaniam A.V., Kono K., Majid A.M.S.A., Oon C.E. (2018). Angiogenesis: Managing the culprits behind tumorigenesis and metastasis. Medicina (Lithuania) 54 (1) : 8. ScholarBank@NUS Repository. https://doi.org/10.3390/medicina54010008
dc.identifier.issn1010660X
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/152203
dc.description.abstractDeregulated angiogenesis has been identified as a key contributor in a number of pathological conditions including cancer. It is a complex process, which involves highly regulated interaction of multiple signalling molecules. The pro-angiogenic signalling molecule, vascular endothelial growth factor (VEGF) and its cognate receptor 2 (VEGFR-2), which is often highly expressed in majority of human cancers, plays a central role in tumour angiogenesis. Owing to the importance of tumour vasculature in carcinogenesis, tumour blood vessels have emerged as an excellent therapeutic target. The anti-angiogenic therapies have been shown to arrest growth of solid tumours through multiple mechanisms, halting the expansion of tumour vasculature and transient normalization of tumour vasculature which help in the improvement of blood flow resulting in more uniform delivery of cytotoxic agents to the core of tumour mass. This also helps in reduction of hypoxia and interstitial pressure leading to reduced chemotherapy resistance and more uniform delivery of cytotoxic agents at the targeted site. Thus, complimentary combination of different agents that target multiple molecules in the angiogenic cascade may optimize inhibition of angiogenesis and improve clinical benefit in the cancer patients. This review provides an update on the current trend in exploitation of angiogenesis pathways as a strategy in the treatment of cancer.
dc.publisherMDPI AG
dc.sourceScopus
dc.subjectAngiogenesis
dc.subjectChemotherapy resistance
dc.subjectComplimentary combination
dc.subjectEndothelial cells
dc.subjectGrowth factor
dc.typeReview
dc.contributor.departmentCANCER SCIENCE INSTITUTE OF SINGAPORE
dc.contributor.departmentDEPT OF SURGERY
dc.description.doi10.3390/medicina54010008
dc.description.sourcetitleMedicina (Lithuania)
dc.description.volume54
dc.description.issue1
dc.description.page8
dc.published.statepublished
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
54-00008.pdf3.36 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.